Structure Therapeutics Inc. (GPCR) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $41.44: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 9.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 12%; Below-average business quality; Negative price momentum.
Structure Therapeutics is a clinical-stage global biopharma developing oral small molecule therapeutics targeting GPCRs. Its lead asset aleniglipron (GLP-1R agonist) is in a Phase 3 registrational program for obesity/overweight; four other candidates are in early clinical... Read more
Sell if holding. Engine safety override at $41.44: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 9.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 12%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.1/10, moderate confidence.
Passes 5/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and earnings proximity 7d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelinealeniglipron10-K Item 1A: 'aleniglipron ... Phase 3 registrational program in chronic weight management'
Material Events(8-K, last 90d)
- 2026-04-15Item 5.02LOWMatthew Lang appointed Chief Operating Officer and General Counsel effective April 15, 2026. Previously CLO at Metsera and Chief Business Officer/CLO at Lyell Immunopharma. No departures noted.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers·1 ceiling hit
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $41.44: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 9.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 12%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $39.46. Score 5.1/10, moderate confidence.
Take-profit target: $97.65 (+135.2% upside). Prior stop was $39.46. Stop-loss: $39.46.
Concentration risk — Pipeline: aleniglipron; Quality below floor (1.6 < 4.0).
Structure Therapeutics Inc. trades at a P/E of N/A (forward -22.5). TrendMatrix value score: 9.0/10. Verdict: Sell.
23 analysts cover GPCR with a consensus score of 4.3/5. Average price target: $109.
What does Structure Therapeutics Inc. do?Structure Therapeutics is a clinical-stage global biopharma developing oral small molecule therapeutics targeting...
Structure Therapeutics is a clinical-stage global biopharma developing oral small molecule therapeutics targeting GPCRs. Its lead asset aleniglipron (GLP-1R agonist) is in a Phase 3 registrational program for obesity/overweight; four other candidates are in early clinical stages. The company has no approved products and no revenue.